Abstracts tagged "Systemic sclerosis"

Abstract Number: 1385 • ACR Convergence 2021
Overall Survival in Patients with Systemic Autoimmune Diseases Following Lung or Heart-Lung Transplantation at a Single High-Volume Academic Transplant Center: A Comparative Cohort Study
Jason Melehani¹, Shufeng Li², Joshua Mooney³ and Lorinda Chung², ¹Stanford University, San Jose, CA, ²Stanford University, Palo Alto, CA, ³Stanford University, Stanford, CA
Background/Purpose: Lung manifestations of systemic autoimmune diseases are a frequent cause of early death. For many patients, current treatments cannot arrest the inexorable progression to…
Abstract Number: 1842 • ACR Convergence 2021
Peripheral Blood Cell Gene Expression Profiling Predicts Response to Mycophenolate in Systemic Sclerosis Related Interstitial Lung Disease
Shervin Assassi¹, Wenjin Zheng², Elizabeth Volkmann³, Xuan Wang⁴, Holly Wilhalme⁵, Marka Lyons⁶, Michael Roth⁵ and Donald Tashkin⁵, ¹University of Texas McGovern Medical School at Houston, Houston, TX, ²School of Biomedical Informatics at the University of Texas Health Science Center at Houston, Houston, TX, ³Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA, ⁴Baylor Scott & White Health, Dallas, TX, ⁵University of California Los Angeles, Los Angeles, CA, ⁶Division of Rheumatology, University of Texas McGovern Medical School at Houston, Houston, TX
Background/Purpose: Response to immunosuppression is variable in systemic sclerosis (SSc) related interstitial lung disease (ILD). Contrary to pulmonary tissue, peripheral blood cell (PBC) RNA can…
Abstract Number: 0142 • ACR Convergence 2021
Description of a Scleroderma Cohort and Management of Lung Disease Risk at a Rural Academic Medical Center
Jenna Marinock¹, P. Daniel Nicholas², Kirsten Koons³, Rakesh Kriplani⁴, Andrea Berger⁴ and David Bulbin⁵, ¹Geisinger Commonwealth School of Medicine, Philadelphia, PA, ²Geisinger Medical Center, Danville, PA, ³Geisinger Medical Center, Lewisburg, PA, ⁴Department of Population Health Sciences, Geisinger Medical Center, Danville, PA, ⁵Geisinger Health System, Danville, PA
Background/Purpose: Systemic sclerosis interstitial lung disease (SSc-ILD) and pulmonary hypertension (SSc-PH) are leading causes of morbidity and mortality in patients with SSc. Few screening guidelines…
Abstract Number: 0406 • ACR Convergence 2021
Gender Differences in Clinical Features and Outcomes of Systemic Sclerosis: Analysis of Reuma.pt/SSc Registry
Raquel Freitas¹, Patrícia Martins², Eduardo Dourado², Tânia Santiago³, Francisca Guimarães⁴, Bruno Fernandes⁵, Salomé Garcia⁶, Beatriz Samões⁷, Ana Pinto⁸, Nuno Gonçalves⁹, Maria Lourenço¹⁰, Emanuel Costa¹¹, Margarida Rocha¹², Maura Couto¹³, Ana Catarina Duarte¹, Filipe Araújo¹⁴, Inês Cordeiro², Fátima Godinho¹, Catarina Resende¹⁵, Maria Joo Salvador¹⁶, Ana Cristina Cordeiro¹ and Maria José Santos¹⁷, ¹Hospital Garcia de Orta, Rheumatology department, Almada, Portugal, ²Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET); Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ³Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁴Unidade Local de Saúde do Alto Minho, Rheumatology department, Ponte de Lima, Portugal, ⁵Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Braga, Portugal, ⁶Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal, ⁷Rheumatology Department, Centro Hospitalar Vila Nova de Gaia, VIla Nova de Gaia, Portugal, ⁸Local Health Unit of Guarda, Portugal, Barcelos, Portugal, ⁹Centro Hospitalar Lisboa Ocidental, Rheumatology Department; Hospital Central do Funchal, Lisboa, Portugal, ¹⁰Hospital Egas Moniz, Barcelos, Portugal, ¹¹Hospital de Braga, Braga, Portugal, ¹²Centro Hospitalar Universitário Lisboa Norte, Rheumatology Department, Faro, Portugal, ¹³Centro Hospitalar Tondela - Viseu, Rheumatology Department, Linda a Velha, Portugal, ¹⁴Hospital de Sant'Ana, Rheumatology and Osteoporosis department, Parede, Portugal, ¹⁵Centro Hospitalar Universitário Lisboa Norte, Rheumatology Department, Lisbon, Portugal, ¹⁶Centro Hospitalar e Universitário de Coimbra, Rheumatology Department, Coimbra, Portugal, ¹⁷Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal
Background/Purpose: Systemic sclerosis (SSc) is a rare connective tissue disease of unknown etiology, with a broad spectrum of clinical and laboratory features. Evidence for the…
Abstract Number: 0555 • ACR Convergence 2021
Pathway-Driven Drug Repositioning in Systemic Sclerosis from Omics Data
Dillon Popovich¹, Tamar Abel¹, Noelle Kosarek², Monica Espinoza³, Rezvan Parvizi⁴, Jonathan Garlick⁵ and Michael Whitfield⁴, ¹Geisel School of Medicine, West Lebanon, NH, ²Dartmouth Geisel School of Medicine, Hartford, VT, ³Geisel School of Medicine, Hanover, NH, ⁴Geisel School of Medicine, Lebanon, NH, ⁵Tufts University School of Dental Medicine, Boston, MA
Background/Purpose: Omic analyses of systemic sclerosis (SSc) skin biopsy datasets identified distinct sets of patients that respond differently to treatment. The goal of this study…
Abstract Number: 1136 • ACR Convergence 2021
Risk of Osteoporosis in Patients with Systemic Sclerosis: A Cross-Sectional Analysis of Two European Prospective Cohorts
Charles Midol¹, Edgar Wiebe², Elise Siegert², Dörte Huscher³, David Launay⁴, Eric Hachulla⁴, Vincent Sobanski¹ and Frank Buttgereit⁵, ¹Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France, Lille, France, ²Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Germany, Berlin, Germany, ³Institute of Biometry and Clinical Epidemiology, and Berlin Institute of Health, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁴Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France, Lille Cedex, France, ⁵Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Patients with systemic sclerosis (SSc) are at high risk for osteoporosis (OPO) and fragility fractures, although their exact prevalences are unknown. This might be…
Abstract Number: 1386 • ACR Convergence 2021
Measurement of TIMP-1 in Pulmonary Vessels May Be a Novel Marker of Reflecting mPAP in CTD-PH
Shusaku Nakashima¹, Kaori Ishikawa¹, Kiyo Ueeda¹, Tomohiro Kameda¹, Hiromi Shimada¹, Risa Wakiya¹, Mansour mai¹, Mikiya Kato¹, Taichi Miyagi², Koichi Sugihara¹, Rina Semba¹, Mao Mizusaki¹ and Hiroaki Dobashi³, ¹Kagawa University, Takamatsu, Japan, ²Kagawa University, Kidagun, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: CTD is a disease with immune abnormalities which could alter normal cytokine profile. CTD-PH has a different pathogenesis from that of iPAH, and immunosuppressive…
Abstract Number: 1843 • ACR Convergence 2021
Perceptions and Concerns Regarding COVID-19 Vaccination in Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort
Jessica Gordon¹, Kimberly Showalter¹, Yin Wu², Linda Kwakkenbos³, Marie-Eve Carrier⁴, Richard Henry², Nora Østbø², Julia Nordlund², Angelica Bourgeault², Mara Canedo Ayala², Marie-Nicole Discepola², Andrea Carboni Jiménez², Christopher Denton⁵, Luc Mouthon⁶, Brett Thombs⁷ and Robert Spiera¹, ¹Hospital for Special Surgery, New York, NY, ²Lady Davis Institute of the Jewish General Hospital, Montréal, QC, Canada, ³Department of Clinical Psychology, Radboud University Behavioural Science Institute, Nijmegen, Netherlands, ⁴Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, ⁵University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁶Hopital Cochin - Paris University, Paris, France, ⁷Lady Davis Institute for Medical Research, Jewish General Hospital; Department of Psychiatry, McGill University, Montréal, QC, Canada
Background/Purpose: Hesitancy about COVID-19 vaccination exists among patients with rheumatic and musculoskeletal diseases, but previous studies have not assessed this specifically in patients with systemic…
Abstract Number: 0143 • ACR Convergence 2021
Economic and Healthcare Resource Use Burden of Systemic Sclerosis
Dinesh Khanna¹, Dan Furst², Justin Li³, Qian Meng⁴, Tamara Lesperance⁵, Kenyatta Peoples⁶, Farah Ali⁵, Brian LaMoreaux⁵ and Stephanie Taylor⁷, ¹University of Michigan, Ann Arbor, MI, ²University of California Los Angeles, Los Angeles, CA, ³Trinity Partners, Waltham, MA, ⁴Trinity Life Sciences, Waltham, MA, ⁵Horizon Therapeutics plc, Deerfield, IL, ⁶Horizon Therapeutics plc, Lake Forest, IL, ⁷Horizon Therapeutics plc, Whitehouse Station, NJ
Background/Purpose: The clinical burden of systemic sclerosis (SSc) is substantial and typically characterized by progressive skin, gastrointestinal, pulmonary, and cardiovascular complications and premature death. The…
Abstract Number: 0407 • ACR Convergence 2021
The Clinical Role of T1 Mapping Cardiac Magnetic Resonance Imaging for Detecting Cardiac Involvement in the Early Stage of Systemic Sclerosis
Munkhtuul Purevsuren¹, Masae Uehara¹, Masato Ishizuka¹, Toru Hara¹, Nobutaka Kakuda¹, Taeko Tsuji¹, Tadashi Yamazaki¹, Miyazaki Miki², Hayakazu Sumida², Ayumi Yoshizaki², Yoshihide Asano², Shinichi Sato³, Masaru Hatano¹ and Komuro Issei¹, ¹1. Department of Cardiovascular Medicine, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan., Tokyo, Japan, ²2. Department of Dermatology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan., Tokyo, Japan, ³Department of Dermatology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is characterized by skin and internal organs tissue fibrosis including the myocardium. Cardiovascular magnetic resonance (CMR) parametric mapping is a promising…
Abstract Number: 0557 • ACR Convergence 2021
The Beta Secretase BACE1 Induces Systemic Sclerosis (SSc) Fibroblast Activation Through the Regulation of the Pro-Fibrotic Notch Signalling Pathway
Christopher Wasson¹, Eva Clavane², Rebecca Ross¹, Paul Meakin² and Francesco Del Galdo³, ¹LIRMM University of Leeds, Leeds, United Kingdom, ²LICAMM University of Leeds, Leeds, United Kingdom, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Extensive work in the Alzheimer’s field has shown BACE1 plays an important role in amyloid beta processing. Additionally, there is evidence showing BACE1 regulating…
Abstract Number: 1150 • ACR Convergence 2021
Use of Energy Conversation Strategies as a Result of the Fatigue Management Education for Individuals with Systemic Sclerosis (FAME-iSS)
Janet Poole¹, Deirdre Connolly² and Kristine Carandang³, ¹University of New Mexico, Albuquerque, NM, ²Trinity Centre for Health Sciences, Dublin, Ireland, ³Independent, San Diego, CA
Background/Purpose: Fatigue remains an understudied symptom of systemic sclerosis (SSc). For other diagnoses, increasing the use of energy conservation strategies, especially pacing. has been associated…
Abstract Number: 1387 • ACR Convergence 2021
Macrovascular Dysfunction and Its Clinical Implication in Systemic Sclerosis
Devender Bairwa¹, Chengappa Kavadichanda², sanket Shah³, Anoop Mathew¹, saikumar dunga³, Aishwarya Gopal³, Molly Mary Thabah¹ and VirSingh Negi¹, ¹Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India, ²JIPMER, Pondicherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
Background/Purpose: Microvascular dysfunction is a key and determining feature of scleroderma (SSc). But contrary to earlier belief there is emerging evidence to suggest co-occurrence of…
Abstract Number: 1844 • ACR Convergence 2021
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated ILD (SSc-ILD) and Differing Comorbidity Burden: Subgroup Analyses of the SENSCIS Trial
Kristin B Highland¹, Teng Moua², Martin Aringer³, Takashi Ogura⁴, Corinna Miede⁵, Margarida Alves⁶ and Virginia Steen⁷, ¹Cleveland Clinic, Cleveland, OH, ²Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, Rochester, MN, ³Rheumatology, Medicine III, University Medical Center & Faculty of Medicine, TU Dresden, Dresden, Germany, ⁴Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Centre, Yokohama, Japan, ⁵mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach, Germany, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁷Division of Rheumatology, Georgetown University, Washington, DC
Background/Purpose: In the SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) vs placebo. Patients with SSc-ILD…
Abstract Number: 0293 • ACR Convergence 2021
Increased Prevalence of Scleroderma Specific Autoantibodies in Seropositive Rheumatoid Arthritis with Lung Involvement
Vasiliki Koulouri¹, Kyriaki Tavernaraki², Mayra Giannelou³ and Clio Mavragani¹, ¹National and Kapodistrian University of Athens, Athens, Greece, ²Imaging and Interventional Radiology, Sotiria General and Chest Diseases Hospital, Athens, Greece, ³Department of Rheumatology, General Hospital of Athens "G. Gennimatas", Athens, Greece
Background/Purpose: To evaluate the prevalence of scleroderma (SSc) specific and anti-Ro52 autoantibodies in seropositive rheumatoid arthritis (RA) patients with lung involvement.Methods: Sera from 67 seropositive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].